0001213900-22-046071.txt : 20220810 0001213900-22-046071.hdr.sgml : 20220810 20220810070046 ACCESSION NUMBER: 0001213900-22-046071 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BiomX Inc. CENTRAL INDEX KEY: 0001739174 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38762 FILM NUMBER: 221150361 BUSINESS ADDRESS: STREET 1: 22 EINSTEIN ST., 4TH FLOOR CITY: NESS ZIONA STATE: L3 ZIP: 7414003 BUSINESS PHONE: (972) 72 394 2377 MAIL ADDRESS: STREET 1: 22 EINSTEIN ST., 4TH FLOOR CITY: NESS ZIONA STATE: L3 ZIP: 7414003 FORMER COMPANY: FORMER CONFORMED NAME: Chardan Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20180430 8-K 1 ea164130-8k_biomxinc.htm CURRENT REPORT
0001739174 false 0001739174 2022-08-10 2022-08-10 0001739174 PHGE:UnitsEachConsistingOfOneShareOfCommonStock0.0001ParValueAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember 2022-08-10 2022-08-10 0001739174 PHGE:SharesOfCommonStock0.0001ParValueMember 2022-08-10 2022-08-10 0001739174 PHGE:WarrantsEachExercisableForOnehalfOfShareOfCommonStock0.0001ParValueAtExercisePriceOf11.50PerShareMember 2022-08-10 2022-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 10, 2022

 

BiomX Inc.
(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-38762   82-3364020
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

22 Einstein St., Floor 4
Ness Ziona, Israel		   7414003
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +972 723942377

 

n/a
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock   PHGE.U   NYSE American
Shares of Common Stock, $0.0001 par value   PHGE   NYSE American
Warrants, each exercisable for one-half of a share of common stock, $0.0001 par value, at an exercise price of $11.50 per share   PHGE.WS   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 10, 2022, BiomX Inc., or the Company, issued a press release announcing its financial results for the second quarter ended June 30, 2022. A copy of the press release issued in connection with the announcement is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit   Description
     
99.1   Press Release dated August 10, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL documents)

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOMX INC.
     
August 10, 2022 By: /s/ Jonathan Solomon
    Name: Jonathan Solomon
    Title: Chief Executive Officer

 

 

2

 

 

 EX-99.1 2 ea164130ex99-1_biomxinc.htm PRESS RELEASE DATED AUGUST 10, 2022

Exhibit 99.1

 

 

 

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

 

Enrollment Continues in Phase 1/2 Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”); results from Part 1 expected by the end of Q3 2022

 

Entered into Second Collaboration with Boehringer Ingelheim to Discover Microbiome Markers for Inflammatory Bowel Disease

 

Announced Publications in the Journals Cell and Bioinformatics

 

Cash Runway Through Multiple Data Readouts and Extended to at Least Mid-2024

 

Company Will Host a Conference Call and Webcast Today at 8:00 am ET

 

BRANFORD, Conn. and NESS ZIONA, Israel – Aug 10, 2022 – BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the second quarter ended June 30, 2022.

 

“It has been an eventful quarter for the Company. We enrolled our first patients in our BX004 cystic fibrosis program, expanded our partnering activities, published important research, and successfully restructured our operations to further extend our cash runway,” said Jonathan Solomon, Chief Executive Officer of BiomX. “With the ongoing enrollment of patients in our CF study, we are one step closer towards reaching an important milestone in the BX004 program. Sites have been opening according to plan and, provided that the pace of enrollment for the study will continue as expected, we continue to anticipate a data readout from the first part of the study by the end of the third quarter of 2022. Our recent KOL event also highlighted the unmet medical need that exists today for so many CF patients who require innovative new therapeutic approaches to help combat these persistent and difficult-to-treat lung infections.

 

“As we enter the second half of 2022, BiomX also remains well positioned financially, with our cash runway now expected to take us through at least mid-2024. Over this period, we expect to reach potential milestones intended to help drive significant shareholder value, and I look forward to sharing additional updates later this year.”

 

RECENT CORPORATE HIGHLIGHTS

 

●In June, BiomX announced the dosing of the first two patients in the Company’s Phase 1b/2a study evaluating BX004 for the treatment of chronic respiratory infections in patients with cystic fibrosis.

 

●Also in June, BiomX announced a second partnership with Boehringer Ingelheim to discover inflammatory bowel disease (“IBD”) microbiome markers. BiomX will utilize its XMarker microbiome-based biomarker discovery platform with the goal of identifying biomarkers for a pathogenic bacterium thought to be associated with IBD. Such biomarkers could help identify IBD patients that would benefit from potential therapies targeted at the microbiome. In September 2020, Boehringer Ingelheim and BiomX entered into their first collaboration, which focused on identifying biomarkers associated with patient phenotypes in IBD.

 

●In August, the Company announced the publication of a scientific paper titled “Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation” in the journal, Cell. The research was conducted across several organizations, including BiomX and the Weizmann Institute of Science (Rehovot, Israel), and presents positive results from a proof-of-concept assessment in a preclinical model of inflammatory bowel disease. The paper is available online at https://www.cell.com/cell/fulltext/S0092-8674(22)00850-9.

 

●On May 12th, the Company hosted a Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa (“PsA”) Infections in CF patients. The live webinar featured presentations from Key Opinion Leaders, Dave Nichols, M.D. and Saima Aslam, M.D., who discussed phage therapy, the current treatment landscape, and the unmet medical need in CF patients with chronic PsA pulmonary infections. The webinar is now available on the Company’s website at https://ir.biomx.com/news-events/ir-calendar/detail/7514/kol-webinar-on-bx004-for-treatment-of-pseudomonas.

 

●Also in May, BiomX announced a corporate restructuring plan intended to extend the Company’s capital resources at least until the middle of 2024. With this plan, the Company reduced its operating costs, which included a reduction in personnel, while prioritizing the ongoing CF program.

 

●Also in May, BiomX announced the publication of a scientific paper titled “Exodus: Sequencing-based Pipeline for Quantification of Pooled Variants” in the journal, Bioinformatics. The research was conducted by scientists at BiomX and is available online at https://doi.org/10.1093/bioinformatics/btac319.

 

 

 

 

 

 

Clinical Program Updates

 

Cystic Fibrosis (BX004)

 

●In June, BiomX announced the dosing of the first two patients in the Company’s Phase 1b/2a study evaluating BX004 for the treatment of chronic respiratory infections in patients with CF.

 

●BX004 is being developed for the treatment of chronic respiratory infections caused by Pseudomonas aeruginosa, a main contributor to morbidity and mortality in patients with CF.

 

●The Phase 1b/2a trial is composed of two parts. Part 1 of the study will evaluate the safety, pharmacokinetics, and microbiologic/clinical activity of BX004 in eight CF patients in a single ascending dose and multiple dose design, with results expected by the end of the third quarter of 2022. Part 2 of the study will evaluate the safety and efficacy of BX004 in 24 CF patients randomized to a treatment or placebo cohort in a 2:1 ratio. Results from Part 2 are expected in the first quarter of 2023.

 

●BiomX has received a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation (“CF Foundation”). The award is structured as an equity investment in which the CF Foundation has agreed to purchase up to $5M million of BiomX common stock across two separate tranches. The first tranche was received on December 21, 2021, with the CF Foundation making an initial equity investment of $3 million. Upon completion of all patient dosing in Part 1 of the Company’s Phase 1b/2a study of BX004, BiomX would have the right to receive the second tranche of $2 million, also as an equity investment.

 

Atopic Dermatitis (BX005)

 

●In April, the United States Food and Drug Administration (“FDA”) approved the Company’s IND application for BX005, which is being developed for the treatment of moderate to severe atopic dermatitis (“AD”).

 

●While the recently announced restructuring is expected to result in a delay to the AD program, the Company plans to support a range of activities that will continue to move this program forward and will provide a more detailed update later in the year.

 

●The Company and Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, entered into an agreement in the second half of 2021 granting Maruho a right of first offer to license BX005 in Japan.

 

●The Company is collaborating with Maruho and working on evaluating timelines for a clinical trial.

 

2

 

 

 

 

Second Quarter 2022 Financial Results

 

●Cash balance, short-term deposits and restricted cash as of June 30, 2022, were $46.7 million, compared to $63.1 million as of December 31, 2021. The decrease was primarily due to net cash used in operating activities. Based upon the Company’s strategic focus on the CF program, the existing cash and cash equivalents are expected to be sufficient to fund the current operating plan through middle of 2024.

 

●Research and development (“R&D”) expenses, net were $4.6 million for the three months ended June 30, 2022, compared to $3.8 million for the same period in 2021. R&D expenses, net were $9.5 million for six months ended June 30, 2022, as well as for the six months ended June 30, 2021. A decrease in Israel Innovation Authority grants resulted in higher R&D expenses, net, offset by a decrease in salaries and related expenses and stock-based compensation expenses due to a reduction in workforce. An additional offset is due to pauses in the development of BX003, the product candidate for the treatment of IBD and primary sclerosing cholangitis, and the colorectal cancer product candidate, as well as due to the discontinuation of the product candidate, BX001, for the treatment of acne.

 

●General and administrative expenses were $2.4 million for the three months ended June 30, 2022, compared to $3.1 million for the same period in 2021. General and administrative expenses were $4.8 million for the six months ended June 30, 2022, compared to $5.6 million for the prior year. The decrease for the six months ended June 30, 2022 was primarily due to a decrease in salaries and related expenses and stock-based compensation expenses due to a reduction in workforce. In addition, the decrease is due to additional expenses incurred in 2021 that resulted from moving into new premises.

 

●Net loss for the second quarter of 2022 was $7.5 million, compared to $7.3 million for the same period in 2021.

 

●Net cash used in operating activities for the six months ended June 30, 2022 was $16.4 million, compared to $12.8 million for the same period in 2021.

 

Conference Call and Webcast Information

 

BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the second quarter 2022. To participate in the conference, please dial 1-877-407-0724 (U.S.), 1-809-406-247 (Israel), or 1-201-389-0898 (International). A live and archived webcast of the call will be available on the Investors section of the Company’s website at www.biomx.com.

 

About BiomX

 

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

 

Additional information is available at www.biomx.com, the content of which does not form a part of this press release.

 

Safe Harbor

 

This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX discusses future updates on its CF, AD and other programs, its expectations regarding the opening of sites, pace of enrollment and timing of the results of the CF trial, the potential safety, tolerability and potential treatment effect of its product candidates, the potential to achieve the applicable clinical milestones required to receive an additional $2 million investment from CFF, and its cash runway, capitalization and financial condition, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2022 and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.

 

3

 

 

 

 

BIOMX INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(USD in thousands, except share and per share data)

(unaudited)

 

   Three Months Ended
June 30,		   Six Months Ended
June 30,		 
   2022   2021   2022   2021 
                 
Research and development (“R&D”) expenses, net   4,584    3,824    9,513    9,494 
Amortization of intangible assets   379    380    759    759 
General and administrative expenses   2,361    3,098    4,838    5,591 
Operating loss   7,324    7,302    15,110    15,844 
                     
Interest expenses   488    -    949    - 
Financial expenses (income), net   (339)   31    (426)   (112)
                     
Loss before tax   7,473    7,333    15,633    15,732 
                     
Tax expenses   9    3    18    6 
                     
Net loss   7,482    7,336    15,651    15,738 
                     
Basic and diluted loss per share of Common Stock   0.25    0.30    0.53    0.65 
                     
Weighted average number of shares of Common Stock outstanding, basic and diluted   29,774,709    24,320,259    29,764,588    24,134,065 

 

4

 

 

 

 

BIOMX INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(USD in thousands, except share and per share data)

(unaudited)

 

   As of 
   June 30,
2022		   December 31,
2021		 
ASSETS        
         
Current assets        
         
Cash and cash equivalents   37,745    62,099 
Restricted cash   963    996 
Short-term deposits   8,000    - 
Other current assets   1,605    3,543 
Total current assets   48,313    66,638 
           
Property and equipment, net   5,252    5,694 
Intangible assets, net   760    1,519 
Operating lease right-of-use assets   4,057    4,139 
Total non-current assets   10,069    11,352 
           
    58,382    77,990 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities          
Trade accounts payable   1,656    2,795 
Other accounts payable   2,394    5,453 
Contract liability   -    1,976 
Current portion of operating lease liabilities   708    819 
Current portion of long-term debt   1,732    - 
Total current liabilities   6,490    11,043 
           
Non-current liabilities          
Contract liability   1,976    - 
Long-term debt, net of current portion   12,929    14,410 
Operating lease liabilities, net of current portion   4,039    4,787 
Other liabilities   209    215 
Total non-current liabilities   19,153    19,412 
           
Stockholders’ equity          
           
Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of June 30, 2022 and December 31, 2021. No shares issued and outstanding as of June 30, 2022 and December 31, 2021.   -    - 
Common Stock, $0.0001 par value; Authorized - 60,000,000 shares as of June 30, 2022 and December 31, 2021. Issued – 29,780,409 shares as of June 30, 2022 and 29,753,238 shares as of December 31, 2021. Outstanding – 29,774,709 shares as of June 30, 2022 and 29,747,538 shares as of December 31, 2021.   2    2 
           
Additional paid in capital   156,872    156,017 
Accumulated deficit   (124,135)   (108,484)
Total stockholders’ equity   32,739    47,535 
    58,382    77,990 

 

5

 

 

 

 

BiomX Contacts:

Investor Relations:
LifeSci Advisors, LLC
John Mullaly
(617)-698-9253
jmullaly@lifesciadvisors.com

BiomX, Inc.
Anat Primovich
Corporate Project Manager
+972 (50) 697-7228
anatp@biomx.com

 

Source: BiomX Inc.

 

 

6 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 phge-20220810.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 phge-20220810_def.xml XBRL DEFINITION FILE EX-101.LAB 6 phge-20220810_lab.xml XBRL LABEL FILE Class of Stock [Axis] Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock Shares of Common Stock, $0.0001 par value Warrants, each exercisable for one-half of a share of common stock, $0.0001 par value, at an exercise price of $11.50 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 phge-20220810_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 10, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 10, 2022
Entity File Number 001-38762
Entity Registrant Name BiomX Inc.
Entity Central Index Key 0001739174
Entity Tax Identification Number 82-3364020
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 22 Einstein St.
Entity Address, Address Line Two Floor 4
Entity Address, City or Town Ness Ziona
Entity Address, Country IL
Entity Address, Postal Zip Code 7414003
City Area Code 972
Local Phone Number 723942377
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock  
Title of 12(b) Security Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock
Trading Symbol PHGE.U
Security Exchange Name NYSEAMER
Shares of Common Stock, $0.0001 par value  
Title of 12(b) Security Shares of Common Stock, $0.0001 par value
Trading Symbol PHGE
Security Exchange Name NYSEAMER
Warrants, each exercisable for one-half of a share of common stock, $0.0001 par value, at an exercise price of $11.50 per share  
Title of 12(b) Security Warrants, each exercisable for one-half of a share of common stock, $0.0001 par value, at an exercise price of $11.50 per share
Trading Symbol PHGE.WS
Security Exchange Name NYSEAMER
XML 9 ea164130-8k_biomxinc_htm.xml IDEA: XBRL DOCUMENT 0001739174 2022-08-10 2022-08-10 0001739174 PHGE:UnitsEachConsistingOfOneShareOfCommonStock0.0001ParValueAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember 2022-08-10 2022-08-10 0001739174 PHGE:SharesOfCommonStock0.0001ParValueMember 2022-08-10 2022-08-10 0001739174 PHGE:WarrantsEachExercisableForOnehalfOfShareOfCommonStock0.0001ParValueAtExercisePriceOf11.50PerShareMember 2022-08-10 2022-08-10 iso4217:USD shares iso4217:USD shares 0001739174 false 8-K 2022-08-10 BiomX Inc. DE 001-38762 82-3364020 22 Einstein St. Floor 4 Ness Ziona IL 7414003 972 723942377 false false false false Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock PHGE.U NYSEAMER Shares of Common Stock, $0.0001 par value PHGE NYSEAMER Warrants, each exercisable for one-half of a share of common stock, $0.0001 par value, at an exercise price of $11.50 per share PHGE.WS NYSEAMER true true EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biomx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea164130-8k_biomxinc.htm ea164130ex99-1_biomxinc.htm phge-20220810.xsd phge-20220810_def.xml phge-20220810_lab.xml phge-20220810_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea164130-8k_biomxinc.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "phge-20220810_def.xml" ] }, "inline": { "local": [ "ea164130-8k_biomxinc.htm" ] }, "labelLink": { "local": [ "phge-20220810_lab.xml" ] }, "presentationLink": { "local": [ "phge-20220810_pre.xml" ] }, "schema": { "local": [ "phge-20220810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 3, "memberStandard": 0, "nsprefix": "PHGE", "nsuri": "http://biomx.com/20220810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea164130-8k_biomxinc.htm", "contextRef": "From2022-08-10to2022-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://biomx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea164130-8k_biomxinc.htm", "contextRef": "From2022-08-10to2022-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "PHGE_SharesOfCommonStock0.0001ParValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares of Common Stock, $0.0001 par value" } } }, "localname": "SharesOfCommonStock0.0001ParValueMember", "nsuri": "http://biomx.com/20220810", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "domainItemType" }, "PHGE_UnitsEachConsistingOfOneShareOfCommonStock0.0001ParValueAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock" } } }, "localname": "UnitsEachConsistingOfOneShareOfCommonStock0.0001ParValueAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember", "nsuri": "http://biomx.com/20220810", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "domainItemType" }, "PHGE_WarrantsEachExercisableForOnehalfOfShareOfCommonStock0.0001ParValueAtExercisePriceOf11.50PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each exercisable for one-half of a share of common stock, $0.0001 par value, at an exercise price of $11.50 per share" } } }, "localname": "WarrantsEachExercisableForOnehalfOfShareOfCommonStock0.0001ParValueAtExercisePriceOf11.50PerShareMember", "nsuri": "http://biomx.com/20220810", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biomx.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001213900-22-046071-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-046071-xbrl.zip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end